Patient: Female, 39-year-old Final Diagnosis: Ovarian carcinoma Symptoms: Abdominal pain • abdominal mass • abdominal tenderness Clinical Procedure: Adjuvant chemotherapy • laparotomy Specialty: Obstetrics and Gynecology • Oncology Objective: Rare disease Background: Ovarian cancer is the leading cause of death in women with gynecological cancers. Ovarian Brenner tumor (BT) is an extremely rare type of epithelial ovarian cancer that accounts for about 1–3% of all ovarian cancers. Herein, we report a rare case of ruptured malignant ovarian Brenner tumor. Case Report: A 39-year-old P0A0 woman came to the Emergency Department (ED) with abdominal pain and tenderness. Perforated appendicitis was initially suspected and an emergency laparotomy was performed by the General Surgery Department. Then, a 25×20×15 cm grayish cystic mass originating from the right adnexa was found. We consulted intraoperatively with the Gynecology Oncology Department and decided to perform complete surgical staging. Histopathological examination confirmed the diagnosis of malignant Brenner tumor (MBT). The patient was then given adjuvant chemotherapy with a paclitaxel carboplatin regimen. In this case report, we present our case along with a review of the current literature regarding the diagnosis and therapy of malignant Brenner tumor. Conclusions: Ovarian MBT is an extremely rare ovarian cancer. Diagnosing MBT can be challenging as there are no clinical, laboratory, or imaging features typical for it. Surgery is the mainstay treatment in MBT cases. The role of adjuvant chemotherapy in MBT is still being debated.

Background: Breast carcinoma is a cancer with the highest number in women, Luminal B is the highest number of all types of invasive breast carcinoma in the world.  Invasive  breast carcinoma of luminal B is breast carcinoma with hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive), and either HER2 positive or HER2 negative with high levels of Ki-67. Determining the aggressiveness factor in  invasive breast carcinoma is very important. PD-L1 is a checkpoint in the cancer cell immunity cycle that affects the aggressiveness of tumour cells and CD133 is a cancerous stem cell marker that plays a role in proliferation, renewal and invasion of tumour cells. This study aims to determine the relationship of PD-L1 and CD133 expression with metastasis in the invasive breast   carcinoma of Luminal B subtype. Methods: This study was an observational analytic study with a case control design to analyze 40 cases of invasive  breast carcinoma Luminal B subtype, then divided into 2 groups, metastasis and nonmetastasis groups of 20 cases respectively. Then, all samples were performed by PD-L1 and CD133 immunohistochemistry staining, and then were associated with metastasis. All data were analyzed statistically, tested with a value of p < 0.05 from a significant level then processed with SPSS 24.0 for Windows. Results: The results of this study indicate that there is a significant relationship in PD-L1 (p = 0.013), CD133 (p = 0.020) with metastasis. PD-L1 expression affects the incidence of metastasis more strongly than the CD133 expression, the high CD133 expression has the greatest risk of metastasis, compared to the high expression in PD-L1 (PD-L1 Odds Ratio : OR CD133 = 7.364 : 12,667). Conclusions: The more increase in expression of PD-L1 and CD133 which demonstrated the more tendency for metastasis shows that PD-L1 had the most influence on metastasis.

Laryngeal carcinoma is a squamous cell malignancy of larynx epithelial with the Indonesian incidence of 2.0 per 100,000 men and 0.2 per 100,000 women. The risk factors of laryngeal carcinoma include age, sex, family history, smoking habit, alcohol drink, and gastroesophangeal reflux disease (GERD)/ laryngopharyngeal reflux (LPR). This study aimed to know some risk factors for laryngeal carcinoma mentioned in Dr. Hasan Sadikin Hospital, Bandung. Hospital-based unmatched case control study was selected as the methods, involving 80 patients in Oncology Clinic of Otorhinolaryngology-Head and Neck Surgery Department, Dr. Hasan Sadikin General Hospital. The medical records of the carcinoma larynx patients was taken as a study instrument. The results were age percentage of 50-79 years old in the case group is 82.5% therefore, it increase the risk of having laryngeal carcinoma by 7.29 times. Male respondents dominate in the case group (90%) with OR =6.00. Respondents with GERD in the case group is 45%, increasing the risk 15.54 times and these results was significant (p<0.005). Other analyzed variables, such as family history, smoking history, and alcohol consumption is not significant statistically (p>0.005). This study shows the results of age, sex, and GERD/LPR are corresponding with the results with previous studies. Otherwise, the results of smoking, alcohol, and family history are not. Therefore, old age, male sex, and GERD increase the risk of having laryngeal carcinoma.

Objective: This study aims to assess the association of subject characteristics and NRAS mutations with HER2 expression in CRC. Methods: This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the Digestive Surgery division at Dr. Hasan Sadikin Hospital. There were 58 study subjects. Examination of NRAS mutations was carried out by Polymerase Chain Reaction (PCR) from fresh tumour tissue obtained from surgery or colonoscopy. Meanwhile, HER2 examination used the Immunohistochemistry (IHC) method of paraffin blocks for anatomical pathology examination of the same patients. Result: HER2 overexpression was found in 6/58 (10.3%) patients with CRC, and from 8 subjects with NRAS mutations, only 1 subject (1.7%) showed overexpression of HER2. Univariate analysis of HER2 expression showed no significant associations to age, sex, histologic feature, tumor location, and NRAS mutations. A significant association was found between HER2 expression and stage of the CRC with p=0.001. Conclusion: There is no association between NRAS mutations and HER2 overexpression in colorectal cancer patients.